Quick Answer
Lucid Diagnostics Inc. reported R&D Expense of $5.68 million for fiscal year 2025.
Lucid Diagnostics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $5.68M | -5.2% |
| 2024 | $5.99M | -17.4% |
| 2023 | $7.25M | -35.6% |
| 2022 | $11.26M | +21.1% |
| 2021 | $9.30M | +70.8% |
| 2020 | $5.44M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.27M | -23.6% | +1.4% |
| June 30, 2025 | $1.25M | -8.5% | -12.1% |
| March 31, 2025 | $1.43M | -4.9% | -14.3% |
| September 30, 2024 | $1.67M | +3.2% | +21.4% |
| June 30, 2024 | $1.37M | -24.9% | -8.6% |
| March 31, 2024 | $1.50M | -20.7% | -7.1% |
| September 30, 2023 | $1.61M | -40.3% | -11.6% |
| June 30, 2023 | $1.83M | -46.9% | -3.5% |
- Lucid Diagnostics Inc. showed a decrease of -5.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Lucid Diagnostics Inc.’s r&d expense has grown by 4.3% (from $5.44 million to $5.68 million).
- The most recent figure is from Lucid Diagnostics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: